Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Journal: The New England journal of medicine
Published: July 29, 2026
Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: July 07, 2026
Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir.
Journal: Journal of clinical pharmacology
Published: March 06, 2026
A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between Islatravir and Lenacapavir.
Journal: Journal of clinical pharmacology
Published: January 09, 2026
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 17, 2025
Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Journal: Antimicrobial agents and chemotherapy
Published: March 22, 2022
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
Journal: HIV research & clinical practice
Published: March 14, 2022
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
Journal: The patient
Published: June 07, 2021
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
Journal: The Journal of antimicrobial chemotherapy
Published: March 11, 2021
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
Journal: Journal of clinical pharmacology
Published: November 06, 2020
Last Updated: 09/26/2026